Bihar's Dry Experiment: How Cough Syrup Became the State's Alcohol Substitute

Bihar's government celebrated a decade of alcohol prohibition in 2026, but the streets of Patna tell a different story. Walk into any pharmacy in the capital's commercial districts and a brief conversation — or sometimes just a knowing look — is enough to gain access to cough syrups containing codeine, an opioid derivative that produces effects similar to alcohol intoxication at a fraction of the cost.

The Indian Express reported in May 2026 that in Bihar, a prohibition state, cough syrup has become the default substitute for those who cannot obtain alcohol legally or afford bootleg liquor, which remains widely available through underground networks. The phenomenon is neither new nor hidden: pharmacists, distributors, and consumers operate in a grey market that state enforcement agencies have repeatedly failed to suppress.

Codeine-based cough syrups — brands like Corex, Phensedyl, and their generic equivalents — sell for between 150 and 400 rupees per bottle in Bihar's grey market, compared to legally taxed alcohol that many lower-income residents cannot afford. A bottle of Indian-made foreign liquor at a licensed store costs a minimum of 200 rupees and often significantly more once state taxes are applied. The price differential alone explains why pharmaceutical diversion has become Bihar's de facto alcohol policy.

The state enacted full prohibition in April 2016 under the Nitish Kumar government, framing the ban as a public health and social justice measure. Officials cited studies linking alcohol consumption to domestic violence, poverty, and poor maternal health outcomes in Bihar's rural communities. The law criminalised possession, sale, and transportation of alcohol. Penalties include imprisonment and vehicle confiscation. Politically, the ban remains popular: surveys have consistently shown majority support among Bihar's female population, who bear a disproportionate share of alcohol-related harm in households where men drink to excess.

But a decade in, the enforcement record is inconsistent at best. Police crackdowns periodically clear pharmacy shelves, but distribution networks re-establish themselves within weeks. The Indian Express coverage documented how consumers in Patna and several district towns navigate the grey market with minimal difficulty, suggesting that prohibition in Bihar functions less as a genuine suppression mechanism and more as a price premium that pushes consumers toward pharmaceutical alternatives.

The health consequences of this substitution are poorly quantified but widely acknowledged. Codeine-dependence produces distinct withdrawal symptoms from alcohol dependency, but both represent serious public health burdens. Medical professionals in Patna's government hospitals have reported increasing presentations of codeine-related complications — respiratory suppression, liver damage from adulterated products, and dependence syndromes among users who began taking cough syrup as alcohol substitutes and escalated to daily use. Without systematic surveillance data, however, the scale of the problem remains largely invisible to policymakers.

Codeine is a controlled substance under India's Drugs and Cosmetics Act, meaning its sale without a valid prescription is technically illegal. In practice, enforcement depends on state drug controller inspections, which critics say are infrequent, underfunded, and susceptible to political interference. Bihar's drug enforcement directorate has roughly 200 inspectors for a population exceeding 120 million. The ratio is roughly one inspector per 600,000 residents — a structural inadequacy that makes comprehensive monitoring impossible regardless of political will.

The pharmaceutical industry maintains formal compliance with export restrictions, selling codeine-containing products through licensed distribution chains in states where they remain legal. The diversion occurs through a secondary market: products enter Bihar through intermediaries who purchase stock in bulk in states like Maharashtra and Uttar Pradesh, where codeine syrups remain available with prescriptions that are routinely issued without adequate medical scrutiny. The supply chain is not a mystery — it is documented in police case files and journalistic investigations. What remains unclear is why successive Bihar administrations have been unable or unwilling to disrupt it systematically.

One structural explanation points to the political economy of prohibition. The ban generates political capital among specific constituencies — women's groups, reform-minded urban voters, and the state's significant Muslim minority, which historically supported the law as a social justice measure. Dismantling prohibition would alienate those constituencies without necessarily winning converts among voters who have adapted to the grey market. Maintaining the ban, even one that is widely circumvented, serves a political function that pure enforcement outcomes do not capture.

A counter-reading holds that Bihar's enforcement failures reflect genuine resource constraints and the difficulty of controlling a substance that enters through legitimate pharmaceutical supply chains rather than clandestine manufacturing. India produces approximately 50 tonnes of codeine annually under international treaty obligations, with the majority allocated to pharmaceutical manufacturers holding government contracts. Tracking the end-use of every bottle manufactured is a logistical challenge that neither Bihar nor any Indian state has solved. The argument is not that prohibition is correct but that the infrastructure required to close the loophole does not yet exist.

What is not in dispute is the human cost of the current arrangement. Residents who turn to codeine syrup as an alcohol substitute face a substance with its own addiction potential, limited medical support infrastructure, and no quality control mechanisms in the grey market. Bottles sold through informal channels may contain correct dosages or may be diluted, adulterated, or past their shelf dates. Users have no recourse when products cause harm. The state that banned alcohol to protect its most vulnerable residents has, in practice, redirected them toward a substitute whose risks are less understood and less acknowledged.

The Indian Express reporting suggests that as of May 2026, the grey market remains functional across Bihar's major urban centres. State officials have announced periodic enforcement operations; the pattern suggests they are designed to generate headlines rather than sustained disruption. A policy that was marketed as a transformation of social relations in Bihar has instead produced a pharmaceutical sideline that serves hundreds of thousands of residents who neither consume legal alcohol nor access any form of substance use support.

The deeper question Bihar's experience raises is not whether prohibition works — the evidence from the state's own data, such as it is, suggests it does not — but what alternatives exist for a state that faces genuine social harm from alcohol misuse and lacks the regulatory infrastructure to implement a more nuanced approach. Legalisation with strict regulation would require administrative capacity Bihar has not demonstrated. Continuation of the current arrangement perpetuates a grey market with its own distinct harms. Neither path is comfortable, which may explain why the state has preferred to announce enforcement operations while allowing the actual market to function.

Bihar's experiment is watched closely by other Indian states that maintain partial or full prohibition — Kerala, Gujarat, and Mizoram among them. If Bihar's policy has failed to suppress substance use while creating a secondary pharmaceutical dependency problem, the lessons extend well beyond Patna's pharmacy counters.

This publication's coverage of Bihar's prohibition policy foregrounds the gap between stated government objectives and documented outcomes on the ground. Unlike wire services that reported the prohibition law's passage and its anniversary milestones, this analysis examines the supply-side adaptation that has defined the policy's decade-long implementation.